DSM Capital Partners LLC Makes New $27.84 Million Investment in DexCom, Inc. (NASDAQ:DXCM)

DSM Capital Partners LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the first quarter, Holdings Channel reports. The firm bought 407,663 shares of the medical device company’s stock, valued at approximately $27,839,000. DexCom accounts for 0.5% of DSM Capital Partners LLC’s portfolio, making the stock its 27th largest position.

Other hedge funds also recently modified their holdings of the company. Golden State Wealth Management LLC boosted its position in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new position in shares of DexCom in the first quarter valued at $27,000. Optiver Holding B.V. acquired a new position in shares of DexCom in the fourth quarter valued at $33,000. Heck Capital Advisors LLC acquired a new position in shares of DexCom in the fourth quarter valued at $38,000. Finally, Alpine Bank Wealth Management acquired a new position in shares of DexCom in the first quarter valued at $40,000. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of recent research reports. Robert W. Baird cut their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Citigroup reiterated a “buy” rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. UBS Group increased their price objective on DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. The Goldman Sachs Group initiated coverage on DexCom in a research note on Friday, May 30th. They set a “buy” rating and a $104.00 price objective for the company. Finally, Oppenheimer increased their price objective on DexCom from $95.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, July 31st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $99.89.

DexCom Price Performance

Shares of DXCM opened at $79.96 on Thursday. The stock has a market cap of $31.36 billion, a P/E ratio of 55.53, a price-to-earnings-growth ratio of 1.68 and a beta of 1.43. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The stock’s 50-day moving average price is $83.28 and its two-hundred day moving average price is $80.19. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%. DexCom’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.43 EPS. On average, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president owned 109,621 shares of the company’s stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the sale, the director directly owned 56,621 shares of the company’s stock, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,656 shares of company stock valued at $2,412,191 over the last 90 days. 0.32% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.